“In the first quarter of 2025 Chemomab continued to successfully deliver on its commitments, achieving two major milestones with transformative potential for both the company and the global primary sclerosing cholangitis community, ” said Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific Officer of Chemomab. “The first was achieving, for the first time, a clear regulatory pathway with the FDA to advance nebokitug to a potential full regulatory approval in PSC. The second was release of our positive 48-week Open Label Extension (OLE) data from the nebokitug Phase 2 SPRING trial-data that confirmed and extended the positive results seen in the 15-week placebo-controlled portion of the study.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMMB:
- Chemomab Therapeutics: Promising Phase 2 Data and Attractive Entry Point Justify Buy Rating
- Chemomab Therapeutics announces presentation of Phase 2 data of CM-101
- Biotech Alert: Searches spiking for these stocks today
- Chemomab Therapeutics reports new clinical data at EASL 2025 on nebokitug
- Chemomab Announces Key Leadership Changes Amid Successful Trial Completion